Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,245,037
  • Shares Outstanding, K 104,775
  • Annual Sales, $ 482,380 K
  • Annual Income, $ 106,140 K
  • EBIT $ 143 M
  • EBITDA $ 137 M
  • 60-Month Beta 0.45
  • Price/Sales 10.34
  • Price/Cash Flow 49.72
  • Price/Book 7.81

Options Overview Details

View History
  • Implied Volatility 62.77% ( +2.68%)
  • Historical Volatility 37.99%
  • IV Percentile 33%
  • IV Rank 34.23%
  • IV High 156.92% on 05/17/24
  • IV Low 13.78% on 08/16/24
  • Put/Call Vol Ratio 0.82
  • Today's Volume 60
  • Volume Avg (30-Day) 1,579
  • Put/Call OI Ratio 1.07
  • Today's Open Interest 38,493
  • Open Int (30-Day) 27,514

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.37
  • Number of Estimates 4
  • High Estimate 0.44
  • Low Estimate 0.26
  • Prior Year 0.28
  • Growth Rate Est. (year over year) +32.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
42.01 +18.42%
on 10/31/24
51.32 -3.06%
on 11/04/24
+4.32 (+9.51%)
since 10/04/24
3-Month
33.34 +49.22%
on 09/04/24
51.32 -3.06%
on 11/04/24
+15.24 (+44.16%)
since 08/05/24
52-Week
20.84 +138.72%
on 04/22/24
51.32 -3.06%
on 11/04/24
+24.13 (+94.18%)
since 11/03/23

Most Recent Stories

More News
New Strong Buy Stocks for November 5th

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:American Assets Trust, Inc. AAT: This self-administered real estate investment trust has seen the Zacks Consensus Estimate for its...

QUAD : 7.24 (+9.37%)
CORT : 50.23 (+0.34%)
ADT : 7.32 (+0.34%)
AAT : 27.39 (+0.96%)
CMA : 63.11 (+1.15%)
Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View

Corcept Therapeutics Incorporated CORT reported third-quarter 2024 earnings of 41 cents per share, which significantly beat the Zacks Consensus Estimate of 27 cents. The company had reported earnings of...

FOLD : 11.37 (+0.35%)
CORT : 50.23 (+0.34%)
ARDX : 5.68 (-3.57%)
ATNM : 1.7800 (+1.14%)
Corcept: Q3 Earnings Snapshot

Corcept: Q3 Earnings Snapshot

CORT : 50.23 (+0.34%)
Zacks.com featured highlights Idaho Strategic, Qifu, Sezzle, Corcept and FinWise

For Immediate ReleaseChicago, IL – October 23, 2024 – Stocks in this week’s article are Idaho Strategic Resources Inc. IDR, Qifu Technology Inc. QFIN, Sezzle Inc. SEZL, Corcept Therapeutics Inc....

CORT : 50.23 (+0.34%)
SEZL : 200.26 (+0.22%)
IDR : 13.25 (-1.05%)
FINW : 16.45 (unch)
QFIN : 33.70 (+2.31%)
5 Stocks With Recent Price Strength to Tap Wall Street Rally

September and October are known as the most disrupting months on Wall Street. Surprisingly, this year, September was quite favorable for market participants. An aggressive 50 basis-point interest rate...

CORT : 50.23 (+0.34%)
SEZL : 200.26 (+0.22%)
IDR : 13.25 (-1.05%)
FINW : 16.45 (unch)
QFIN : 33.70 (+2.31%)
Implied Volatility Surging for Corcept Therapeutics (CORT) Stock Options

Investors in Corcept Therapeutics Incorporated CORT need to pay close attention to the stock based on moves in the options market lately. That is because the Nov 15, 2024 $12 Put had some of the highest...

CORT : 50.23 (+0.34%)
Zacks.com featured highlights include Corcept Therapeutics, Abercrombie & Fitch and HCI Group

For Immediate ReleaseChicago, IL – October 10, 2024 – Stocks in this week’s article are Corcept Therapeutics Inc. CORT, Abercrombie & Fitch Co. ANF and HCI Group, Inc. HCI.3 Strong Buy Momentum Stocks...

CORT : 50.23 (+0.34%)
ANF : 134.87 (-2.13%)
HCI : 113.24 (+0.85%)
3 Strong Buy Momentum Stocks as Bull Market Nears 2-Year Mark

Entering the fourth quarter of 2024, Wall Street maintained strong momentum, positively closing the first nine months. The S&P 500, the Dow and the Nasdaq gained 20.8%, 12.3% and 21.2%, respectively, in...

CORT : 50.23 (+0.34%)
ANF : 134.87 (-2.13%)
HCI : 113.24 (+0.85%)
Here's Why Investors Should Consider Buying Corcept Stock Now

Corcept Therapeutics’ CORT sole-marketed drug, Korlym (mifepristone), which is approved for treating Cushing's syndrome, has been performing well. The drug has been witnessing strong demand in the past...

CORT : 50.23 (+0.34%)
KRYS : 172.73 (+1.10%)
ANIP : 56.25 (+0.43%)
BVS : 10.51 (-23.34%)
Promising Progress in Oncology as Cancer Deaths Decline and Research Grows

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group – With the recent wrapping up of...

ONCY : 1.1400 (+0.44%)
CORT : 50.23 (+0.34%)
ILMN : 151.40 (-1.36%)
CSTL : 33.96 (+0.95%)
NUVL : 89.21 (-0.36%)
ONC.TO : 1.58 (-1.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Corcept is focused on the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncology disorders which are associated with the activity of the hormone cortisol, also known as the stress hormone. Corcept's only marketed drug, Korlym (mifepristone),...

See More

Key Turning Points

3rd Resistance Point 55.40
2nd Resistance Point 53.36
1st Resistance Point 51.71
Last Price 50.23
1st Support Level 48.02
2nd Support Level 45.98
3rd Support Level 44.33

See More

52-Week High 51.32
Last Price 50.23
Fibonacci 61.8% 39.68
Fibonacci 50% 36.08
Fibonacci 38.2% 32.48
52-Week Low 20.84

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar